Influence of the first radioactive iodine ablation on peripheral complete blood count in patients with differentiated thyroid cancer

Hu, Tianpeng; Meng, Zhen; Zhang, Guizhi; Jia, Qiang; Tan, Jian; Zheng, Wei; Wang, Renfei; Li, Xue; Liu, Na; Zhou, Pingping; Upadhyaya, Arun

doi:10.1097/md.0000000000004451

Cited by 20 publications

(19 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The decline in Hb was no longer statistically significant when categorized by sex. This pattern of marrow suppression is in agreement with those of previous studies, demonstrating a significant decrease in platelets and WBC, with relative sparing of Hb [15][16][17][18][19].…”

Section: Discussionsupporting

confidence: 92%

“…Our study is the first to show effects of RAI treatment on bone marrow function within a very short period. RAI treatment for ablation of postoperative thyroid remnants or for treatment of recurrent and metastatic disease has been found to be associated with bone marrow suppression, but the small change was not found to be clinically significant for adverse events (such as severe neutropenia or anemia, requiring transfusion or administration of showed that significant decline in Hb at 6 months after treatment in each gender [16,18]. However the decrease of Hb in each gender was not statistically significant in this study.…”

Section: Discussioncontrasting

confidence: 61%

See 1 more Smart Citation

Short-term bone marrow suppression in differentiated thyroid cancer patients after radioactive iodine treatment

Kim

et al. 2020

Endocr J

View full text Add to dashboard Cite

After thyroidectomy in differentiated thyroid cancer (DTC), radioactive iodine (RAI) treatment is often used for remnant ablation. However, RAI treatment has been associated with bone marrow suppression, and leukopenia, anemia, and thrombocytopenia may occur after a single RAI administration. In this study, we examined the change in complete blood counts at 1 week after RAI administration; this is less well studied. A group of 189 DTC patients who received RAI treatment and underwent blood tests before and after treatment, were included. Peripheral blood counts at baseline were compared to those obtained at 1 week, 1-6 months, and 6-12 months after RAI treatment in order to test for bone marrow suppression. At 1 week after RAI treatment, there was a significant decrease in the white blood cell count (WBC, 5.8 ± 1.6 × 10 9 /L vs. 5.4 ± 1.5 × 10 9 /L, p < 0.001) and hemoglobin level (Hb, 13.5 ± 1.7 g/dL vs. 13.3 ± 1.4 g/dL, p = 0.001). The WBC decrease was mostly due to lymphocyte counts (2.2 ± 0.6 × 10 9 /L vs. 1.6 ± 0.5 × 10 9 /L, p < 0.001), with no decrease in the neutrophil count. Although not significantly changed at 1 week, platelets counts were altered within 6 months (265 ± 69 × 10 9 /L vs. 239 ± 53 × 10 9 /L, p < 0.001). The decline in the WBC count recovered within 6 months; lymphocyte and platelet counts recovered within 12 months. In conclusion, RAI treatment after a thyroidectomy was associated with a statistically significant but temporary decline in WBC counts and Hb levels at 1 week. Physicians treating DTC patients should not decrease usage of moderate dose RAI treatments.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussioncontrasting

confidence: 61%

Short-term bone marrow suppression in differentiated thyroid cancer patients after radioactive iodine treatment

Kim

et al. 2020

Endocr J

View full text Add to dashboard Cite

show abstract

“…In previous studies, blood samples of patients with thyroid cancer treated with I-131 were reported to show temporary leukopenia, anemia and thrombocytopenia, and persistent cytopenia was observed in patients exposed to high doses of I-131 (18)(19)(20). Also, a risk of cancer in patients who exposed to low dose IR for diagnosis and treatment was reported and development of acute and chronic myeloid leukemia was reported in patients who were exposed to IR for a long time.…”

Section: Discussionmentioning

confidence: 97%

Cytogenetic Studies of Chromosome Abnormalities in Thyroid Cancer Patients Before and After Iodine-131 Treatment

Öden¹,

Atasoy²,

Demır³

et al. 2019

Bezmialem Science

View full text Add to dashboard Cite

Objective: Thyroid cancer is among the most common endocrine malignancies. Initial management consists surgery and ablation. I-131,which is used to damage surgically unremoved thyroid tissue or treat metastases, is a source for ionizing radiation (IR), also generates potential mutagenic and carcinogenic effects.The purpose of research is to investigate the damage on chromosomes at the I-131 treatment of thyroid cancer patients exposed to the same dose of genotoxic agent. Methods: Peripheral blood of 20 patients and 20 healthy control individuals were used in study. Materials were collected from patients before the I-131 treatment and three times on the 15 th day, the first and second month after the I-131 treatment. All chromosome abnormalities, spontaneous chromosomal breakages, and sister chromatid exchange (SCE) were analyzed by cytogenetic methods in the samples. Results: The results obtained from peripheral blood of patiens who received ablation therapy revealed no significant increase for chromosome breakages, chromosome abnormalities, and SCE. Karyotyped metaphase spreads showed none of the structural and numerical chromosome abnormalities.The results of chromosome breakages and SCE have been statistically assessed by Aspin Welch test and did not differ from the control group.The t values of this variability were found to be-1.001,-1.654, respectively, and p>0.05. Conclusion: Our results demonstrate that applied therapeutic clinical dose does not show cytogenetic abnormalities risks of the early period in patients. I-131 treatment is a good option for the treatment of thyroid cancer,but also we recommend that physicians should perform long term follow-up examinations for IR exposed patients and prevent possible complications.

show abstract

“…A study by Padovani et al [ 23 ] showed a statistically significant decrease in Hb and PLT count 1 year after treatment in 50 patients who received ≥9250 MBq of 131 I. A clinical study by Hu et al [ 11 ] also showed that administration of approximately 3700 MBq of 131 I was associated with significant declines in WBC, PLT, and lymphocyte counts that persisted for at least 6 months after ablation. Tofani et al [ 24 ] showed that 10 patients (group A) who underwent whole-body scintigraphy with 185 MBq of 131 I only had a reduction in natural killer cells on Days 7 and 15.…”

Section: Discussionmentioning

confidence: 99%

“…131 I therapy also leads to bone marrow toxicity and can cause bone marrow dysfunction [ 10 ]. Some studies have shown that both a single dose and multiple doses of 131 I therapy can change complete blood count (CBC) [ 11 , 12 ]. However, the influence of 131 I therapy on CBC in patients with DTC is debatable.…”

Section: Introductionmentioning

confidence: 99%

Effect of ¹³¹I Therapy on Complete Blood Count in Patients with Differentiated Thyroid Cancer

Rui

Zheng

et al. 2021

Med Sci Monit

Self Cite

View full text Add to dashboard Cite

Background The aim of this study was to investigate the effects of 131 I therapy on complete blood count (CBC) in patients with differentiated thyroid cancer (DTC). Materia/Methods We analyzed CBC in 542 patients with DTC who were grouped according to treatment cycles and cumulative dose and then subdivided by sex and age. The effects of 131 I therapy among the different groups and subgroups were analyzed. Results After sorting patients by treatment cycles and doses, 131 I therapy was found to have different effects on CBC depending on patient sex and age. The effect on white blood cell (WBC) counts persisted longer in women, while increases in hemoglobin (Hb) were more significant in men. The influence on red blood cell (RBC) counts was short-lived in patients aged 45 to 54 years. Monocyte counts were significantly decreased only in patients aged 55 years and older who had undergone 3 or 4 treatment cycles. In men, CBC was more affected by cumulative dose. 131 I therapy only influenced platelet and monocyte counts in patients aged 55 years or older. Hb was significantly decreased and increased in the high- and low-dose groups, respectively. No significant complications were observed during follow-up. Conclusions 131 I therapy had a greater impact on WBC counts in women, while changes in RBC counts and Hb were more obvious in men. During 131 I therapy, clinicians should pay attention to different CBC indicators based on a patient’s sex and age, but risks associated with an altered CBC are unlikely to outweigh the benefits of 131 I. The results of the present study may help alleviate the concerns of a large proportion of patients with DTC and their families about the effects of 131 I therapy on CBC.

show abstract

Influence of the first radioactive iodine ablation on peripheral complete blood count in patients with differentiated thyroid cancer

Cited by 20 publications

References 24 publications

Short-term bone marrow suppression in differentiated thyroid cancer patients after radioactive iodine treatment

Short-term bone marrow suppression in differentiated thyroid cancer patients after radioactive iodine treatment

Cytogenetic Studies of Chromosome Abnormalities in Thyroid Cancer Patients Before and After Iodine-131 Treatment

Effect of ¹³¹I Therapy on Complete Blood Count in Patients with Differentiated Thyroid Cancer

Contact Info

Product

Resources

About